Top 10 Diets for 2023: US News &amp; World Report Rankings

Prioritizing Blood-Based CRC Tests May Lead to Higher Costs and Worse Outcomes, Study Finds

News

Slideshow

US News and World Report recently released its annual "Best Diets" ranking for 2023. The full report includes 38 plans, both well recognized and not-so-familiar. To give you a glimpse of what patients may be reading, Patient Care Online highlights how the top 10 diets rank on a scale of 0 to 5 stars, overall and on: Fast weight loss, overall weight loss, ease of following, and how healthy the diet is.

Related Content

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Annual colorectal cancer screening with FIT was the most cost-effective strategy among patients with low adherence, researchers reported.

Keith A. Reynolds

October 1st 2024

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Grace Halsey

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

October 25th 2023

DEA Amends Telehealth Prescribing Rules, Including Special Registration for Schedule II-V Medications

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Austin Littrell

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

The DEA action includes 3 new telehealth rules that make permanent several flexibilities enacted during the pandemic and also establish new protections for patients.

Patient Care Staff

Prioritizing Blood-Based CRC Tests May Lead to Higher Costs and Worse Outcomes, Study Finds

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

Related Content

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Annual colorectal cancer screening with FIT was the most cost-effective strategy among patients with low adherence, researchers reported.

Keith A. Reynolds

October 1st 2024

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Grace Halsey

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

October 25th 2023

DEA Amends Telehealth Prescribing Rules, Including Special Registration for Schedule II-V Medications

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Austin Littrell

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

The DEA action includes 3 new telehealth rules that make permanent several flexibilities enacted during the pandemic and also establish new protections for patients.

Patient Care Staff